Recon: UK halts Valneva’s chikungunya vaccine; CDC terminates all vaccine advisory committee members
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- Several hundred NIH employees sign a letter of protest to the agency’s director (STAT)
- RFK Jr. removes all members of CDC panel advising U.S. on vaccines (CNBC)
- Trump’s ‘gold standard’ order is a blueprint for politicizing science (STAT)
- Trump Drug Price Plan Risks Fallout for Medicaid, Beneficiaries (Bloomberg Law)
- Senate Republicans Plan to Release Major Revisions to Trump’s Tax Bill (Bloomberg)
- NIH scientists speak out over estimated $12 billion in Trump funding cuts (Reuters)
- Pfizer CEO: no commitments made in drug price meetings with US government (Reuters)
- Novo's Ozempic linked to rare cases of serious eye disorder, EU regulator says (Reuters)
- UK's MHRA suspends Valneva's chikungunya vaccine for elderly (Reuters)
- UnitedHealth eyes $1 billion deal to exit Latin America as insurer refocuses on US, sources say (Reuters)
- Contraceptives for poorest countries stuck in warehouses after US aid cuts (Reuters)
- Mpox is still a health emergency, WHO says (Reuters)
- A cautious culture cost Novo Nordisk its lead in the obesity drug race, former employees say (STAT)
- Metsera’s amylin drug shows early potential for substantial weight loss (STAT)
- Otsuka tops Vera Therapeutics in kidney disease study showdown (STAT)
- Merck's potential blockbuster cholesterol pill succeeds in late-stage studies (Reuters)
- Sixth Street-backed Caris Life Sciences targets $5.3 billion valuation in US IPO (Reuters)
- Sanofi leans into 'first-mover advantage' by shipping Beyfortus early, as RSV antibody market set to heat up (Endpoints)
- Is there still hope for Summit's cancer drug buried in the data? (Endpoints)
- Kelun's $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids (Endpoints)
- MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D (Endpoints)
- These blood tests for cancer are increasingly popular. Experts still aren’t sure how best to use them (STAT)
- As Omada goes public, executives reflect on why profits are elusive in digital health (STAT)
- Medtech Caris Life Sciences Seeks to Raise $423.5 Million in IPO (Bloomberg)
- Medtronic removes tracheostomy tubes due to dislodging risk (MedTech Dive)
- Owens & Minor spikes $1.36B Rotech buyout over regulatory barriers (MedTech Dive)
- Outset Medical appoints Renee Gaeta as CFO (MedTech Dive)
- Ultrahuman Launches Home Health Monitoring (MedTech Insight)
- Mondelez CEO sees shoppers remaining thrifty (Food Business News)
- Conagra to sell seafood brands Van de Kamp’s and Mrs Paul’s for $55M (Food Dive)
- How Nerds Gummy Clusters became a big hit in candy (Food Dive)
- California Bill Would Remove Ultra-Processed Foods from School Lunches (Food Safety)
- RFK Jr.’s chronic disease agency would eliminate or reduce funding for some prevention programs (STAT)
- Philanthropies rush to save measles surveillance network pushed to brink of collapse by U.S. cuts (STAT)
- FDA reassures rare disease advocates that ‘being flexible’ is plan for gene therapy (STAT)
- Pharma imports into the US return to normal after March tariff stockpiling (Endpoints)
- Judge rules J&J unit must pay $442M in antitrust case (MedTech Dive)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
